The bear case on Eli Lilly has played out, says only firm to have called it a sell

HSBC analysts, led by Rajesh Kumar, have upgraded Eli Lilly (LLY) shares from 'reduce' to 'hold' and raised their price target from $675 to $700. This upgrade signals that HSBC, notably the sole firm with a prior 'sell' rating, believes the bear case has now played out following market reactions to the drug manufacturer's oral obesity drug trial, potentially indicating a broader shift in analyst sentiment.

Analysis

HSBC, previously the sole firm with a sell-equivalent rating on Eli Lilly (LLY), has upgraded the stock to 'hold' from 'reduce' and lifted its price target to $700 from $675. This revision is predicated on the view that the bear case for the company has now fully played out, specifically following the market's reaction to the trial results for its oral obesity drug. The upgrade from the most prominent dissenter is significant, signaling a belief that near-term downside risks have been priced in and that the stock's valuation is now more balanced. The shift from a 'reduce' to a 'hold' rating, rather than an outright 'buy', suggests that while the immediate negative catalysts may have subsided, HSBC still perceives limited upside from current levels, framing this as a neutralization of a bearish stance rather than the adoption of a bullish one.

Key Decisions for Investors

• The upgrade from the only sell-side bear suggests downside risk has likely diminished, providing a rationale for investors to maintain current long positions in Eli Lilly.
• Given the upgrade is to 'hold' with a new $700 price target, the perceived upside is limited, warranting caution for investors looking to initiate new positions at current price levels.
• Investors should recognize that this sentiment shift is tied to the market's digestion of recent trial news, and should continue to monitor the competitive landscape and future data readouts in the obesity market as key potential catalysts.